Cittadine Andrew
SEC CIK 1863624 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics | COO | 57.9K | $149.6K | — | 39 | 2022-06-30 | 2026-06-30 |
Most active insiders at MNPR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Tsuchimoto Kim R | Dir | — | $911.1K |
| 2 | Anderson Raymond | Dir | — | $703.0K |
| 3 | KLAUSNER ARTHUR J | Dir | — | $343.9K |
| 4 | Vu Quan Anh | CFO | $104.9K | — |
| 5 | RIOUX PATRICE | Acting Chief Medical Off | — | $111.26 |
| 6 | Cittadine Andrew | COO | — | — |
| 7 | Hendricks Diane | 10% | — | — |
| 8 | Robinson Chandler | CEO, Dir | — | — |
Transactions 39
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-02 19:37 | 2026-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +5,254 | 57.9K | +10% | — |
| D | 2026-07-02 19:37 | 2026-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $92.59 | -2,309 | 55.6K | -4% | -$213.8K |
| D | 2026-04-02 15:03 | 2026-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +3,514 | 54.2K | +7% | — |
| D | 2026-04-02 15:03 | 2026-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $54.79 | -1,571 | 52.7K | -3% | -$86.1K |
| D | 2026-01-05 | 2025-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +4,326 | 52.6K | +9% | — |
| D | 2026-01-05 | 2025-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $65.30 | -1,889 | 50.7K | -4% | -$123.4K |
| D | 2025-10-02 | 2025-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +4,327 | 50.2K | +9% | — |
| D | 2025-10-02 | 2025-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $81.67 | -1,896 | 48.3K | -4% | -$154.8K |
| D | 2025-07-02 | 2025-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $35.78 | -2,990 | 45.9K | -6% | -$107.0K |
| D | 2025-07-02 | 2025-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +6,863 | 48.8K | +16% | — |
| D | 2025-04-02 | 2025-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +1,791 | 42.7K | +4% | — |
| D | 2025-04-02 | 2025-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $36.41 | -744 | 42.0K | -2% | -$27.1K |
| D | 2025-01-02 | 2024-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +1,790 | 41.7K | +4% | — |
| D | 2025-01-02 | 2024-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $22.00 | -721 | 40.9K | -2% | -$15.9K |
| D | 2024-10-02 | 2024-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +1,791 | 40.4K | +5% | — |
| D | 2024-10-02 | 2024-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $6.74 | -535 | 39.9K | -1% | -$3,606 |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $0.73 | -2,019 | 193.1K | -1% | -$1,474 |
| D | 2024-07-02 | 2024-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +8,952 | 195.1K | +5% | — |
| M | 2024-06-21 | 2024-06-18+ | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | P - Purchase | $0.7843 | +32.5K | 186.1K | +21% | +$25.5K |
| M | 2024-06-17 | 2024-06-13+ | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | P - Purchase | $0.9133 | +36.0K | 153.6K | +31% | +$32.9K |
| M | 2024-06-05 | 2024-06-03+ | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | P - Purchase | $0.77 | +24.0K | 117.6K | +26% | +$18.5K |
| M | 2024-05-31 | 2024-05-29+ | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | P - Purchase | $0.64 | +36.0K | 81.6K | +79% | +$23.0K |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +8,952 | 60.7K | +17% | — |
| D | 2024-04-02 | 2024-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $0.68 | -3,098 | 57.6K | -5% | -$2,107 |
| D | 2024-01-03 | 2023-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +8,952 | 54.9K | +19% | — |
| D | 2024-01-03 | 2023-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $0.34 | -3,098 | 51.8K | -6% | -$1,053 |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +8,953 | 48.5K | +23% | — |
| D | 2023-10-03 | 2023-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $0.62 | -2,624 | 45.9K | -5% | -$1,627 |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $0.86 | -4,057 | 39.6K | -9% | -$3,489 |
| D | 2023-07-03 | 2023-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +13.8K | 43.6K | +46% | — |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +4,063 | 31.0K | +15% | — |
| D | 2023-04-04 | 2023-03-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $1.39 | -1,154 | 29.8K | -4% | -$1,604 |
| D | 2023-01-03 | 2022-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +4,062 | 28.3K | +17% | — |
| D | 2023-01-03 | 2022-12-31 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $2.37 | -1,406 | 26.9K | -5% | -$3,332 |
| M | 2022-11-16 | 2022-11-14+ | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | P - Purchase | $3.09 | +16.1K | 24.2K | +196% | +$49.7K |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +4,063 | 9,376 | +76% | — |
| D | 2022-10-03 | 2022-09-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $1.52 | -1,191 | 8,185 | -13% | -$1,810 |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | F - Tax | $2.30 | -2,812 | 5,313 | -35% | -$6,468 |
| D | 2022-07-01 | 2022-06-30 | MNPR | Monopar Therapeutics | Cittadine Andrew | COO | M - OptEx | — | +8,125 | 8,125 | New | — |
Purchase Sale Sale after option exercise All abbreviations